2 stories mentioning CRNXUpdated 35d ago
Every FINWIRES story that references CRNX, newest first.
ALX Oncology (ALXO) said Monday it named Jeff Knight as chief development and operating officer, effective immediately.The company said Knight most recently served in the same role at Crinetics Pharmaceuticals (CRNX).Shares of ALX were up over 8% in Monday trading.Price: $1.88, Change: $+0.18, Percent Change: +10.59%
Jeff E. Knight, Chief Development & Operating Officer, on April 08, 2026, sold 85,163 shares in Crinetics Pharmaceuticals (CRNX) for $3,415,036. Following the Form 4 filing with the SEC, Knight has control over a total of 105,289 common shares of the company, with 105,289 shares held directly.SEC Filing:https://www.sec.gov/Archives/edgar/data/1658247/000162828026024716/xslF345X05/wk-form4_1775853233.xml